ArticleNeurochemical research2026
Adolescent M-CSF Administration Provides Durable Protection Against Trauma-Induced PTSD-Like Phenotypes in Male Mice Through Microglia-Dependent Mechanisms.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Post-traumatic stress disorder (PTSD) is a severe psychiatric condition for which effective preventive strategies are lacking. Innate immune preconditioning has shown promise for the prevention of PTSD, yet the transient nature of such protection when induced in adulthood poses a substantial limitation. Using male C57BL/6J mice, we tested whether administration of macrophage colony-stimulating factor (M-CSF, 100 µg/kg, intraperitoneally) during adolescence, a developmental period characterized by heightened microglial plasticity, could establish enduring resilience against trauma-induced PTSD-like behaviors. Mice received a single M-CSF injection at postnatal day 28 (PND28) and were subsequently subjected to single prolonged stress (SPS/FS) at 4, 16, or 32 weeks thereafter, with behavioral and molecular assessments conducted at PND70, PND154, and PND266, respectively. Our results showed that adolescent M-CSF exposure substantially prevented SPS/FS-induced anxiety-like behaviors assessed by the elevated plus maze and open field test, and SPS/FS-induced fear-like behaviors evaluated by contextual and cued fear conditioning tests, at all three post-administration intervals. Concurrently, M-CSF pretreatment prevented SPS/FS-induced interleukin-1β (Il-1β), Il-6, and tumor necrosis factor-α (Tnf-α) mRNA expression within the hippocampus and medial prefrontal cortex across all time points examined. These protective phenotypes were eliminated when microglial function was pharmacologically inhibited or when microglia were depleted before M-CSF administration, establishing that microglial integrity at the time of adolescent immune challenge is required for the establishment of long-term resilience. Taken together, these findings demonstrate that a single developmental immune intervention confers lifelong protection against SPS/FS-induced PTSD-like behaviors through microglia-dependent mechanisms, introducing a vaccine-like paradigm for the prevention of PTSD.
Indexed as
Identifiers
42900437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.